QUANTIFYING THE SOCIAL VALUE GAINED FROM THERAPEUTIC INNOVATION IN MULTIPLE MYELOMA IN SPAIN: A MULTIDIMENSIONAL ASSESSMENT
Author(s)
Jorge Mestre-Ferrandiz, PhD1, Fernando Abdalla Pereira, MsC1, Coral González Martínez, PhD1, Paula Gómez-Plana Rodríguez, MsC1, Paula Pereira, PhD1, Elena García, MsC1, Joaquín Martínez López, MD, PhD, MBA2, Maria victoria Mateos, PhD3, Marta Trapero, PhD4, VICENTE GIMENO BALLESTER, PhD5, NURIA RUIZ, MsC6, Angela Motilla Peñarrubia, MsC6, RAFAEL PARRA GABILONDO, MsC6, David Beas Pedraza, MSc6, Marta Bañón Medina, MsC6, Alvaro Hidalgo Vega, PhD7.
1Weber, Madrid, Spain, 2Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain, 3Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain, 4Departamento de Economía Aplicada, Universitat de Lleida, Lleida, Spain, 5Servicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, Spain, 6Johnson & Johnson Innovative Medicine, Pozuelo de Alarcón, Spain, 7Universidad de Castilla-La Mancha, Toledo, Spain.
1Weber, Madrid, Spain, 2Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain, 3Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain, 4Departamento de Economía Aplicada, Universitat de Lleida, Lleida, Spain, 5Servicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, Spain, 6Johnson & Johnson Innovative Medicine, Pozuelo de Alarcón, Spain, 7Universidad de Castilla-La Mancha, Toledo, Spain.
OBJECTIVES: Therapeutic innovation in multiple myeloma (MM) has transformed clinical practice, yet its value is usually captured through clinical endpoints alone. This study quantified the broader social value gained from MM innovation in Spain across clinical, economic and humanistic value dimensions.
METHODS: A bottom-up model of MM care in Spain was developed over a ten-year horizon (2017-2026): thirty-two treatment combinations across thirty-one variables, stratified by treatment line (1L-4L+) and, in first line, by transplant eligibility. An adapted equipercentile linking methodology, a well-established technique for mapping between health-status instruments, was applied to map literature-based QALYs reported for each combination onto EQ-5D values derived from a dedicated multiple myeloma patient survey. This tied each combination to a specific patient profile and its associated resource use and other variables. Social value gained was calculated from the difference (delta) in each of these variables between a combination and the reference (least-effective) combination in its line; each delta was multiplied by the number of patients receiving the combination and by the monetary value assigned to that difference. The model has been validated with HEOR and clinical experts through an iterative process.
RESULTS: Preliminary results show that social value gained is consistently higher in earlier treatment lines, indicating that earlier treatment leads to greater social value. It also increases steadily over the study period, reflecting a sustained rise in social value alongside successive therapeutic innovation.
CONCLUSIONS: Accounting for the social value of therapeutic innovation is of growing relevance to society and to healthcare systems, as it captures benefits that extend well beyond clinical endpoints alone. Validated, multidimensional models such as the one developed here offer an innovative means of quantifying this value and inform decision-making in MM, supporting the integration of non-clinical criteria into HTA.
METHODS: A bottom-up model of MM care in Spain was developed over a ten-year horizon (2017-2026): thirty-two treatment combinations across thirty-one variables, stratified by treatment line (1L-4L+) and, in first line, by transplant eligibility. An adapted equipercentile linking methodology, a well-established technique for mapping between health-status instruments, was applied to map literature-based QALYs reported for each combination onto EQ-5D values derived from a dedicated multiple myeloma patient survey. This tied each combination to a specific patient profile and its associated resource use and other variables. Social value gained was calculated from the difference (delta) in each of these variables between a combination and the reference (least-effective) combination in its line; each delta was multiplied by the number of patients receiving the combination and by the monetary value assigned to that difference. The model has been validated with HEOR and clinical experts through an iterative process.
RESULTS: Preliminary results show that social value gained is consistently higher in earlier treatment lines, indicating that earlier treatment leads to greater social value. It also increases steadily over the study period, reflecting a sustained rise in social value alongside successive therapeutic innovation.
CONCLUSIONS: Accounting for the social value of therapeutic innovation is of growing relevance to society and to healthcare systems, as it captures benefits that extend well beyond clinical endpoints alone. Validated, multidimensional models such as the one developed here offer an innovative means of quantifying this value and inform decision-making in MM, supporting the integration of non-clinical criteria into HTA.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE223
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Biologics & Biosimilars, Genetic, Regenerative & Curative Therapies, Oncology, Personalized & Precision Medicine